FOLD

Amicus Therapeutics, Inc.

11.13 USD
+0.02 (+0.18%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Amicus Therapeutics, Inc. stock is down -1.59% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.94% of the previous 16 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 2 CALLs, 2 PUTs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 Oct 15:07 19 Jan, 2024 12.00 CALL 20000 297
20 Oct 16:52 20 Oct, 2023 11.00 PUT 4000 5123
08 Nov 15:56 19 Apr, 2024 13.00 PUT 318 2
09 Nov 20:15 19 Apr, 2024 11.00 CALL 222 97

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases.